Docetaxel is a chemotherapy indicated for:
- Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
- Docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.
- Docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.
- Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors over-express HER2 and who previously have not received chemotherapy for metastatic disease.
- Docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.
- Doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 overexpressing, node-positive or high risk node-negative, breast cancer.
- Docetaxel in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer.
- Docetaxel is indicated for the treatment of patients with advanced non-small cell lung carcinoma.
Ovarian cancer
- Docetaxel is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy.
Prostate cancer
- Docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.
Esophageal cancer
- Docetaxel for the treatment of esophageal cancer.
- Docetaxel for the treatment of advanced gastric cancer.
Head and neck (SCCHN)
- Docetaxel as monotherapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.
- Docetaxel in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
